Reuters: Hot Stocks: CORRECTED-(June 20)-UPDATE 1-FDA says Pozen's aspirin combo may need more data

Reuters: Hot Stocks Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

CORRECTED-(June 20)-UPDATE 1-FDA says Pozen's aspirin combo may need more data Jun 21st 2012, 16:42 Thu Jun 21, 2012 12:42pm EDT (Corrects drug descriptor in headline and paragraph one) June 20 (Reuters) - U.S. health regulators informed Pozen Inc that they have come to a preliminary determination that the company's experimental drug to prevent stomach ulcers related to aspirin use did not show bioequivalence with 325 mg aspirin, further jeopardizing the drug's chances to win approval soon. Pozen's shares were down 19 percent in extended trade, after closing at $7.45 Wednesday on the Nasdaq. The stock had plunged by nearly a third in April, when the U.S. Food and Drug Administration suggested the company also seek approval for a lower version of the drug, and that it may limit the drug to a smaller-than-expected patient population. In a regulatory filing Wednesday, Pozen said the FDA now advised it that its lower dose drug would also likely need an in vivo bioequivalence study to win approval. Pozen had said in April that it did not intend to conduct a new study for the lower dose and would instead submit existing data in support of the application. At the time, the company said it expected its filing for marketing approval to be delayed by six months. The oral, once-daily drug is a combination of aspirin and AstraZeneca's Prilosec, a commonly used gastric medicine. If approved, the pill would offer a convenient alternative to patients who would otherwise have to take these two drugs separately. Pozen said on Wednesday it planned a follow-up call with the FDA in the next few weeks to determine the next steps in satisfying the bioequivalence requirements and any impact on the approval filing timeline. (Reporting by Shailesh Kuber in Bangalore; Editing by Anthony Kurian) Link this Share this Digg this Email Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions